Auremolimab

N/A

Report date: 2022/10/18 16:55:06

Base Information

Drug NameAuremolimab
Drug Alias NameVM-6
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-2 receptor beta chain antagonists
TargetsInterleukin-2 receptor beta chain
Therapy Area/IndicationsVitiligo
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesN/A
Active IndicationsVitiligo
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A